Dengue virus envelope protein domain I/II hinge: A key target for dengue virus vaccine design?

Expert Review of Vaccines

Volumn 14, Issue 1, 2014, Pages 5-8

  Widman, Douglas G ^a   Baric, Ralph S ^a,b  

^a The University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

antibodies; dengue; epitope; protection; serotype; vaccine

Indexed keywords

DENGUE VACCINE; EPITOPE; VIRUS ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY RESPONSE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; HINGE REGION; NONHUMAN; PROTEIN DOMAIN; REVIEW; VIRUS NEUTRALIZATION; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROTEIN TERTIARY STRUCTURE;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; DENGUE VIRUS; EPITOPES, B-LYMPHOCYTE; HUMANS; PROTEIN STRUCTURE, TERTIARY; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84917674057     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.961431     Document Type: Review

References (20)

1. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012;380(9853):1559-67
2. Hss AS, Koh MT, Tan KK, et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine 2013;31(49):5814-21
3. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014. [Epub ahead of print
4. Mukherjee S, Dowd KA, Manhart CJ, et al. Mechanism and Significance of Cell Type-Dependent Neutralization of Flaviviruses. J Virol 2014;88(13):7210-20
5. Rivino L, Kumaran EA, Jovanovic V, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 2013;87(5): 2693-706
6. Harenberg A, Begue S, Mamessier A, et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother 2013;9(11):2317-25
7. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006;2(2): 60-7
8. Poo J, Galan F, Forrat R, et al. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naive Children, Adolescents, and Adults in Mexico City: randomized Controlled Phase 1 Trial of Safety and Immunogenicity. Pediatr Infect Dis J 2010. [Epub ahead of print
9. Capeding RZ, Luna IA, Bomasang E, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011;29(22):3863-72
10. Dowd KA, Pierson TC. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 2011;411(2):306-15
11. Wahala WM, Kraus AA, Haymore LB, et al. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 2009;392(1):103-13
12. de Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 2012;109(19):7439-44
13. Smith SA, de Alwis R, Kose N, et al. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis 2013;207(12):1898-908
14. Messer WB, Yount B, Hacker KE, et al. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl Trop Dis 2012; 6(2):e1486
15. Messer WB, de Alwis R, Yount BL, et al. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci USA 2014;111(5):1939-44
16. VanBlargan LA, Mukherjee S, Dowd KA, et al. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog 2013; 9(12):e1003761
17. Lok SM, Kostyuchenko V, Nybakken GE, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 2008;15(3):312-17
18. Ferlenghi I, Clarke M, Ruttan T, et al. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell 2001;7(3):593-602
19. Osorio JE, Velez ID, Thomson C, et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis 2014; 14(9):830-8
20. Cassetti MC, Thomas SJ. Dengue human infection model: introduction. J Infect Dis 2014;209(Suppl 2):S37-9